FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies specifically binding to TIGIT (immunoreceptor of T-cells with domains Ig (immunoglobulin) and ITIM (tyrosine-containing inhibitory motif of immunoreceptor), or antigen-binding fragments of antibodies, as well as compositions containing them. Also disclosed are a nucleic acid molecule coding antibodies or antigen-binding fragments thereof, an expression vector and a host cell for the expression of antibodies or antigen-binding fragments thereof, and therapeutic use of the antibodies.
EFFECT: invention can find further application in cancer therapy.
19 cl, 7 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2014 |
|
RU2663795C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
